Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,782   +0,016   (+2,09%) Dagrange 0,768 - 0,792 3.814.802   Gem. (3M) 4M

(Gesloten) Donderdag 29/11/2012

88 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste | Omlaag ↓
  1. [verwijderd] 29 november 2012 16:42
    Ready for the Restart and the FDA; Reiterate Buy; Target to $0.16

    Biotech company Pharming Group NV announces the analyst report completed by Joseph Pantginis, Ph.D. and Raluca Pancrotov, Ph.D. from Roth Capital Partners is published today.

    Based on recent positive Phase III data for Ruconest (under SPA) and a $10 million milestone cash infusion from partner Santarus, we believe Pharming is poised for an important restart. We anticipate BLA filing for acute attacks of HAE in 1H13 and U.S. approval in 1H14. We believe Ruconest represents a competitive threat to Cinryze and Berinert based on both efficacy and a differentiated safety profile. We reiterate our Buy rating.

    Click Here For Print Version of Full Report (Adobe Acrobat Required)
    Click Here For Full Report in HTML (for mobile users)

    About ROTH Capital Partners
    ROTH is an investment banking firm dedicated to the small-cap public market. Since its inception in 1984, ROTH has been an innovator in this market. Headquartered in Newport Beach, CA, ROTH has regional offices in San Diego, Los Angeles, Seattle, New York and Pennsylvania. International offices include a Shanghai Representative Office and a Hong Kong Limited Office.

    Contact
    Sijmen de Vries, CEO: T: +31 524 7400

    "This update is for informational purposes only and is not viewed by Pharming to be of a price sensitive nature"

    link: roth2.bluematrix.com/sellside/EmailDo...
88 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.